Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

iTabMed Approved to Start China Trials of CD3 Bi-specific for Solid Tumors

publication date: Jun 7, 2023

Shanghai iTabMed was approved to start China clinical trials of A-337, a CD3-activating bi-specific antibody targeting EpCAM, in patients with advanced solid tumors. The company says EpCAM is up-regulated and over-expressed in many solid tumors. A-337 was developed using iTabMed’s immunotherapy antibody (iTab™) platform. iTab™ is a T cell engager platform for human CD3-activating bi- and tri-specific antibodies targeting tumor associated antigens. A-337 has a similar structure to its lead candidate, A-319, which has started Phase I trials for patients with liquid tumors. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital